- Home
- VBIO vs SHPH Comparison
VBIO vs SHPH Comparison
Compare VBIO & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VBIO | SHPH |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | 52 | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6M | 1.9M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | VBIO | SHPH |
|---|---|---|
| Price | $0.32 | $3.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 530.1K | ★ 1.4M |
| Earning Date | N/A | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.25 | $0.38 |
| 52 Week High | $0.61 | $6.15 |
Technical Indicators
Market Signals| Indicator | VBIO | SHPH |
|---|---|---|
| Relative Strength Index (RSI) | 36.73 | 51.96 |
| Support Level | $0.25 | $2.81 |
| Resistance Level | $0.51 | $3.56 |
| Average True Range (ATR) | 0.07 | 0.36 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 25.86 | 22.33 |
Price Performance
Historical ComparisonAbout VBIO Valion Bio Inc. Common Stock
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.
About SHPH Shuttle Pharmaceuticals Holdings Inc.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.